Search Hotels in Sausalito

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2

May 16, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of...

2 Healthcare Stocks to Keep an Eye On and 1 to Ignore

May 15, 2025

SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm

Topics Stocks

Exposures COVID-19 US Equities

May 14, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm

Topics Fraud

Exposures Legal

May 14, 2025

These 3 pharma stocks have oversold RSIs and solid analyst support, setting up potential bounce-back trades through this week and next

Topics Fraud

Exposures Legal

Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore

May 14, 2025

Via MarketBeat

Topics Earnings

Exposures Financial Product Safety

Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%

May 13, 2025

Roche's APHINITY study shows promising results for HER2-positive breast cancer treatment with Perjeta regime

Via Benzinga

Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy

May 13, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying

May 13, 2025

Via The Motley Fool

Topics Cannabis Law Enforcement

Exposures Cannabis Legal

Benzinga Bulls And Bears: IBM, Novavax, Arm Holdings — And UK Trade Deal Boosts Markets

May 10, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

May 09, 2025

From Pomerantz LLP

Via GlobeNewswire

SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm

May 09, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm

Topics Fraud

Exposures Legal

May 09, 2025

RADNOR, PA - May 9, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of...

Topics Fraud

Exposures Legal

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

May 09, 2025

Via Benzinga

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference

May 08, 2025

SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm

May 08, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm

Topics Fraud

Exposures Legal

May 08, 2025

RADNOR, PA - May 8, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Sarepta...

Topics Fraud

Exposures Legal

Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)

May 07, 2025

SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm

Topics Artificial Intelligence

Exposures Artificial Intelligence

May 07, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm

Topics Fraud

Exposures Legal

May 07, 2025

RADNOR, PA - May 7, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 20.5% in the afternoon session after the company reported weak first quarter 2025 results which featured drastically lowered full-year...

Topics Fraud

Exposures Legal

Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why

May 07, 2025

Sarepta posted a deeper-than-expected Q1 loss and cut its 2025 forecast due to Elevidys rollout delays, despite beating revenue estimates.

Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up

May 07, 2025

Via Benzinga

The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low

May 07, 2025

Sarepta stock plummeted Wednesday on a "double whammy" that includes its trimmed 2025 sales outlook and a critical FDA appointment.

Via Investor's Business Daily

Topics Death

Exposures Death Product Safety

Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation

May 07, 2025

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.

Via Benzinga

Exposures Product Safety

Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results

May 07, 2025

Via Benzinga

Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

May 07, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

May 07, 2025

Via Benzinga

Why Porch Group Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket

May 07, 2025

Via Benzinga

Sarepta Shares Slide To 2017 Lows On Revenue Cut, But Retail Bulls Remain Defiant

May 06, 2025

Despite strong Q1 sales led by Elevidys, Sarepta raised spending forecasts and lowered full-year guidance, triggering a sharp market reaction.

Via Stocktwits

Sarepta Therapeutics (NASDAQ:SRPT) Surprises With Q1 Sales But Stock Drops 22.8%

May 06, 2025

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 80.2% year on year to $744.9 million. Its non-GAAP loss of $3.42 per...